BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636 [PMID: 36187401 DOI: 10.4251/wjgo.v14.i9.1622]
URL: https://www.wjgnet.com/2220-315x/full/v14/i9/1622.htm
Number Citing Articles
1
Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral HepatitisDiagnostics 2023; 13(16): 2631 doi: 10.3390/diagnostics13162631
2
Jian Yang, Jialuo He, Yiting Feng, Ming Xiang. Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodelingFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1166440
3
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III RecommendationsJournal of Clinical and Experimental Hepatology 2024; 14(1): 101269 doi: 10.1016/j.jceh.2023.08.005
4
Min Dai, Rashid N. Lui, Louis H.S. Lau. The role of gut microbiome and fecal microbiota transplantation in liver cancer and related complications: mechanisms and therapeutic potentialsHepatoma Research 2023;  doi: 10.20517/2394-5079.2023.33
5
Chi Zhang, Huihui Shao, Zunsheng Han, Bo Liu, Jing Feng, Jie Zhang, Wenxuan Zhang, Kun Zhang, Qingyun Yang, Song Wu. Development and In Vitro–In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver DiseaseInternational Journal of Molecular Sciences 2023; 24(15): 12328 doi: 10.3390/ijms241512328
6
Mehmet Akce, Bassel F El-Rayes, Narendra Wajapeyee. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapyOncogene 2023; 42(14): 1051 doi: 10.1038/s41388-023-02646-1